Navigation Links
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Date:9/3/2009

; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax((TM)) under the HHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, unexpected financial obligations that could increase the rate of our cash consumption, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for both Valortim((R)) and the Company's 3G rPA anthrax vaccine candidate. At this point there can be no assurance that either of these product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC Bulletin Board: ... is focused on spotlighting the company,s focus on acquiring high-growth ... located at www.chinaagrotech.com. , , About ... headquartered in Singapore, is focused on becoming a leader in ...
... , , Intelligent Design Author Will Also Speak ... , Sept. 14 The debate over Darwin rages on in ... of Natural History September 29th with the Southwestern debut of ... in the fossil record. To view a trailer and clips from the ...
... , SUNNYVALE, Calif., Sept. 14 ... focused on developing and commercializing innovative small molecule drugs for ... that it will report financial results for the fourth quarter ... market closes on Thursday September 17, 2009 at 1:30 p.m. ...
Cached Biology Technology:Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept. 29 2Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call 2
(Date:7/9/2014)... fit in terms of cardiorespiratory capacity, strength and ... adolescents are more obese and present higher levels ... the centre-north of Europe. , These are some ... conducted by scientists from the University of Granada ... other European research groups. The study compared the ...
(Date:7/9/2014)... cell divides, it must first make a copy of its ... that occurs billions of times a day in the human ... tools that cells use to replicate DNAthe enzymes that unzip ... a clear picture of how the process works. , Now, ... to decipher what goes on at the "replication fork"the point ...
(Date:7/8/2014)... Collectors found the first two specimens of the prickly plant ... decades, the 14-inch-tall plant was identified wrongly as one species, ... a long search turned up a "pathetic, wilted" third specimen ... the spiny plant as a new, possibly endangered species and ... found in Valentine, Texas, population 134 in 2010. , Most ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4New plant species from the heart of Texas 2New plant species from the heart of Texas 3New plant species from the heart of Texas 4New plant species from the heart of Texas 5
... of North Carolina at Chapel Hill have identified a new ... practice. In an article published in the ... researchers describe how exploiting the molecular mechanism behind acupuncture resulted ... new therapeutic approach PAPupuncture. Principal investigator Mark ...
... defects of the brain and spine in America,s babies, particularly those of Hispanic ... with the B vitamin folic acid, according to a new petition filed with ... , Gruma Corporation Spina ... March of Dimes Foundation , ...
... surgery appears to be associated with an increased risk of ... a new study at the Sahlgrenska Academy, at the University ... is the most important factor when it comes to adhesive ... operations and other health conditions into account. This is ...
Cached Biology News:Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment 2Coalition petitions FDA to fortify corn masa flour with folic acid 2Coalition petitions FDA to fortify corn masa flour with folic acid 3
... Cycler unit is an inexpensive personal or mini ... PCR process. Lightweight, with a small footprint, it ... including the researcher's desk. , The Gene Cycler ... do not have access to a large laboratory ...
... Select Immunophosphatase Secondary Detection System is intended ... Prediluted Primary Antibody reagents, which contain rat ... of antigens by light microscopy in paraffin-embedded ... System may also be used with other ...
... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
Biology Products: